

Ref: PSH-CS 37/2022

The operating results of Pruksa Holding Public Company Limited ("the Company") for 2Q22 was mainly derived from the revenue from real estate business. Tables of presale comparison by product segment for the three months and six months ended June 30, 2022 and 2021 are as follows.

			Unit	: Bt million
Products	2Q22	2Q21	Increase (Decrease)	% Change
Townhouse	3,439	4,185	(746)	(17.8)
Single-detached house	1,857	1,718	139	8.1
Condominium	1,046	1,322	(276)	(20.9)
Total	6,342	7,225	(883)	(12.2)

Products	1H22	1H21	Increase (Decrease)	% Change
Townhouse	6,239	7,968	(1,729)	(21.7)
Single-detached house	3,563	3,497	66	1.9
Condominium	1,884	2,700	(816)	(30.2)
Total	11,686	14,165	(2,479)	(17.5)

Note: All presale was reported as net presale (net presale = presale - promotion).

In 1H22, the Company recorded real estate presale at Bt11,686 million, decreased by Bt2,479 million or 17.5% compared to the same period last year. The decrease was from townhouse and condominium businesses of Bt1,729 million and Bt816 million, respectively. While single-detached house presale rose by Bt66 million following a stronger demand for housing.

Performance comparison of the Company for the three months ended June 30, 2022 and 2021

Unit: Bt millio					llion	
Statement of income	2Q22	%	2Q21	%	Increase/ (Decrease)	%ҮоҮ
Revenue from sales of real estate	5,214	96.8	6,473	101.3	(1,259)	(19.5)
Promotions	(113)	(2.1)	(139)	(2.2)	(26)	(18.7)
Revenue from sales of real estate - net	5,101	94.7	6,334	99.1	(1,233)	(19.5)
Revenue from hospital operations	203	3.8	28	0.4	175	625.0
Other Income	85	1.6	27	0.4	58	214.8
Total Revenues	5,389	100.0	6,389	100.0	(1,000)	(15.7)

Unit: Bt million



Statement of income	2Q22	%	2Q21	%	Increase/ (Decrease)	%YoY
Cost of sales of real estate	(3,451)	(67.7)	(4,484)	(70.8)	(1,033)	(23.0)
Cost of hospital operations	(210)	(103.4)	(72)	(257.1)	138	191.7
Gross profit	1,643	31.0	1,806	28.4	(163)	(9.0)
Selling and Administrative expenses	(1,087)	(20.2)	(1,099)	(17.2)	(12)	(1.1)
Profit from operating activities	641	11.9	735	11.5	(94)	(12.8)
Finance costs	(91)	(1.7)	(146)	(2.3)	(55)	(37.7)
Share of profit / (loss) of joint ventures accounted for using equity method	9	0.2	(1)	(0.0)	10	944.2
Profit before income tax expense	559	10.4	588	9.2	(29)	(4.9)
Tax expense	(120)	(2.2)	(150)	(2.3)	(30)	(20.0)
Profit for the period	439	8.1	438	6.9	1	0.2
Non-controlling interests	(9)	(0.2)	(11)	(0.2)	(2)	(18.2)
Owners of the parent	430	8.0	427	6.7	3	0.7

Remark: Percentage in statement of income is calculated from total revenues, while percentage of cost of sales of real estate and cost of hospital operations is calculated from revenue from net sales of real estate and revenue from hospital operations, respectively. Gross profit is calculated from revenue from net sales of real estate and revenue from hospital operations.

Performance comparison of the Company for the six months ended June 30, 2022 and 2021

					Unit: E	Bt million
Statement of income	1H22	%	1H21	%	Increase/ (Decrease)	%YoY
Revenue from sale of real estate	11,004	96.8	13,524	101.8	(2,520)	(18.6)
Promotions	(224)	(2.0)	(302)	(2.3)	(78)	(25.8)
Revenue from sales of real estate-net	10,780	94.8	13,222	99.5	(2,442)	(18.5)
Revenue from hospital operations	447	3.9	29	0.2	418	1,441.4
Other Income	143	1.3	38	0.3	105	276.3
Total Revenues	11,370	100.0	13,289	100.0	(1,919)	(14.4)
Cost of sales of real estate	(7,391)	(68.6)	(9,536)	(72.1)	(2,145)	(22.5)
Cost of hospital operations	(436)	(97.5)	(74)	(255.2)	362	489.2
Gross profit	3,400	30.3	3,641	27.5	(241)	(6.6)
Selling and Administrative expenses	(2,076)	(18.3)	(2,137)	(16.1)	(61)	(2.9)
Profit from operating activities	1,467	12.9	1,542	11.6	(75)	(4.9)
Finance costs	(210)	(1.8)	(290)	(2.2)	(80)	(27.6)
Share of profit of joint ventures accounted for using equity method	23	0.2	106	0.8	(83)	(78.0)
Profit before income tax expense	1,280	11.3	1,357	10.2	(77)	(5.7)
Tax expense	(278)	(2.4)	(302)	(2.3)	(24)	(7.9)
Profit for the period	1,002	8.8	1,055	7.9	(53)	(5.0)
Non-controlling interests	(20)	(0.2)	(21)	(0.2)	(1)	(4.8)



Statement of income	1H22	%	1H21	%	Increase/ (Decrease)	%YoY
Owners of the parent	982	8.6	1,034	7.8	(52)	(5.0)

Remark: Percentage in statement of income is calculated from total revenues, while percentage of cost of sales of real estate and cost of hospital operations is calculated from revenue from net sales of real estate and revenue from hospital operations, respectively. Gross profit is calculated from revenue from net sales of real estate and revenue from hospital operations.

Revenues

In 2Q22, the Company reported revenue of Bt5,101 million from sale of real estate, Bt203 million from hospital operations, which Vimut hospital has commenced operation since May 2021, and Bt85 million from other income, resulted in total revenue of Bt5,389 million.

In 1H22, the Company reported revenue of Bt10,780 million from sale of real estate, Bt447 million from hospital operations, which Vimut hospital has commenced operation since May 2021, and Bt143 million from other income, resulted in total revenue of Bt11,370 million.

Revenue from sales of real estate business by product segment for the six months ended June 30, 2022 and 2021 including

	Unit: Bt milli					
Product Type		1H Rev	Increase			
	2022	%	2021	%	(Decrease)	%YoY
Townhouse	5,012	46.5	6,934	52.4	(1,922)	(27.7)
Single-detached house	2,311	21.4	3,129	23.7	(818)	(26.1)
Condominium	2,814	26.1	3,159	23.9	(345)	(10.9)
Others *	643	6.0	0	0.0	643	100.0
Revenue from sale real estate	10,780	100.0	13,222	100.0	(2,442)	(18.5)

* Revenue from Land Sale

1H22 revenue from real estate business was Bt10,780 million, a decrease of Bt2,442 million or 18.5% YoY. This was due to a decrease in townhouse revenue of Bt1,922 million or 27.7%, single-detached house revenue of Bt818 million or 26.1% and condominium revenue of Bt345 million or 10.9%. While the Company reported revenue from land sale at Bt643 million in 1H22.

Cost

In 2Q22, the Company reported cost of real estate sales of Bt3,451 million or 67.7% of net revenue from real estate compared to Bt4,484 million or 70.8% of net revenue from real estate in 2Q21. The Company also reported cost of hospital operations of Bt210 million or 103.4% of revenue from hospital operations compared to Bt72 million which was from the commencement of Vimut Hospital in 2Q21.



In 1H22, the Company reported cost of real estate sales of Bt7,391 million or 68.6% of net revenue from real estate compared to Bt9,536 million or 72.1% of net revenue from real estate in 1H21. The Company also reported cost of hospital operations of Bt436 million or 97.5% of revenue from hospital operations compared to Bt74 million which was from the commencement of Vimut Hospital in 2Q21.

Gross profit margin

In 2Q22, the Company reported gross profit margin of 31.0%, increased from the same period last year at 28.4% due to a decrease in cost of real estate sales ratio.

In 1H22, the Company reported gross profit margin of 30.3%, increased from the same period last year at 27.5%, due to a decrease in cost of real estate sales ratio.

Selling & Administrative expenses

In 2Q22, the Company reported selling and administrative expenses of Bt1,087 million or 20.2% of total revenue, dropped by Bt12 million or 1.1% from last year.

In 1H21, the Company reported selling and administrative expenses of Bt2,076 million or 18.3% of total revenue, dropped by Bt61 million or 2.9% from last year. The decrease was from selling expenses of Bt111 million or 11.9%.

Finance costs

In 2Q22, the Company reported finance costs of Bt91 million, a decrease of Bt55 million from the same period last year. This was mainly from the bond redemption in 1Q22 and 2Q22 totaling Bt5,500 million. During 2Q22, the Company also entered into interest swap contract.

In 1H21, the Company reported finance costs of Bt210 million, a decrease of Bt80 million from the same period last year. This was mainly from the bond redemption in 1Q22 and 2Q22 totaling Bt5,500 million. During 2Q22, the Company also entered into interest swap contract.

As of June 30, 2022, interest-bearing debt to equity ratio was relatively low at 0.41 times and net interest-bearing debt to equity ratio was 0.39 times, following an effective debt management of the Company and its subsidiaries.

Share of profit / (loss) of joint ventures accounted for using equity method

In 1H21, the Company recognized the share of profit of joint ventures accounted for using equity method of Bt106 million. This was due to Vimut Hospital Holding Co., Ltd., a subsidiary of the Company, acquired the shares and voting interests of 51% of the issued and paid-up share capital in Theptanyapa Co., Ltd on February 1, 2021. It is



an owner and operator of Theptarin Hospital as well as holds shares in 5 subsidiaries, comprising DM Food Co., Ltd., Lab Plus One Co., Ltd., Intervention Consulting at Theptarin Hospital Co., Ltd., Theptarin Dental Center Co., Ltd., and Contours Express (Thailand) Co., Ltd. The transaction was reported as an investment in joint venture and consisted of a cash payment of Bt708.7 million and incurred acquisition-related costs of Bt15.6 million.

Profit

In 2Q22, profit for the Company recorded at Bt430 million or 8.0% of total revenue, increased by Bt3 million or 0.7% YoY. Net profit margin increased by 1.3 percentage points from 2Q21.

In 1H22, profit for the Company recorded at Bt982 million or 8.6% of total revenue, down by Bt52 million or 5.0% YoY, due largely to profit from joint venture of Bt106 million during 1H21. Net profit margin increased by 0.8 percentage points from the same period last year.

Consolidated statement of financial position

	June 30,	December 31,		June 30,	December 31,
	2022	2021		2022	2021
	(Bt m	illion)		(Bt m	nillion)
Assets			Non-interest bearing debt		
			Trade accounts payable	1,261	1,350
Current Assets			Other liabilities	7,299	7,518
Cash and cash equivalents	1,030	3,348	Total non interest bearing debt	8,560	8,868
Real estate development for sale	54,135	56,756	Short-term loans	420	4
Other current assets	1,649	1,771	Current portion of long-term loans	-	400
			Long-term loans	2,536	457
			Current portion of long-term debentures	4,750	9,500
			Long-term debentures	10,000	8,750
Total current assets	56,814	61,875	Total interest bearing debt	17,706	19,111
Property, plant and equipment	6,490	6,566	Total liabilities	26,266	27,979
Other non-current assets	6,538	3,610	Equity	42,836	43,324
Total non-current assets	13,028	10,176	Non-controlling interests	740	748
Total assets	69,842	72,051	Total liabilities and equity	69,842	72,051

Remark: Extracts of consolidated statement of financial position



As of June 30, 2022, the Company reported 140 active projects with total project value of Bt144,955 million, which were categorized by product segment including 82 townhouse projects with total value of Bt65,467 million, 40 single-detached house projects with total value of Bt45,115 million, and 18 condominium projects with total value of Bt34,373 million.

As of June 30, 2022, the Company reported total assets of Bt69,842 million. A YoY decrease was mainly from lower amount of real estate development for sale. Interest-bearing debt (IBD) consists of short-term loans of Bt420 million, long-term loans of Bt2,536 million and long-term debentures of Bt14,750 million with the main purpose set on liquidity management and uses of working capital.

(Miss Surawee Chaithumrongkool) Group Chief Financial Officer

Investor Relations Dept.:	Ms. Tipnipa Kananub	E-mail: tipnipa_k@pruksa.com	Tel: 02-080-1739
Accounting Dept.:	Ms. Jintana Insee	E-mail: jintana_i@pruksa.com	Tel: 02-080-1739